QSAR study on dual 5-HT1A and 5-HT1B antagonists: An insight into the structural requirement for antidepressant activity

Archiv der Pharmazie

Volumn 341, Issue 5, 2008, Pages 314-322

  Dessalew, Nigus ^a  

^a ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

Depression; QSAR; Serotonine autoreceptors; Thienopyrimidinones; TSAR

Indexed keywords

CGP 4718; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PRC 025; PYRIMIDINONE DERIVATIVE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1B ANTAGONIST; UNCLASSIFIED DRUG; VN 222; ANTIDEPRESSANT AGENT; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN ANTAGONIST;

ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; MOLECULAR MODEL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; ANIMAL; CERCOPITHECUS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; TUMOR CELL LINE; VERO CELL;

ANIMALS; ANTIDEPRESSIVE AGENTS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; HUMANS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN ANTAGONISTS; VERO CELLS;

EID: 46449097898     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200700224     Document Type: Article

References (39)

1. C. Holden, Science 2000, 288, 39-40.
2. F. Kerrigan, Exp. Opin. Ther. Pat. 1998, 8, 439-460.
3. E. J. Nestler, M. Barrot, R. J. Dileone, A. J. Eisch, et al., Neuron 2002, 34, 13-25.
4. M. K. Sun, D. L. Alkon, Curr. Drug Targets 2002, 1, 575-592.
5. V. J. Nalepa, Eur. J. Pharmacol. 2000, 405, 351-363.
6. V. Snow, S. Lascher, Ann. Intern. Med. 2000, 132, 738-742.
7. J. W. Williams, C. D. Mulrow, E. Chiquette, P. Noel, et al., Ann. Intern. Med. 2000, 132, 743-751.
8. D. Spinks, G. Spinks, Curr. Med. Chem. 2002, 9, 799-810.
9. S. Peretti, R. Judge, I. Hindmarch, Acta. Psychiatr. Scand. 2000, 403, 17-25.
10. D. N. Middlemiss, G. W. Price, J. M. Watson, Curr. Opin. Pharmacol. 2002, 2, 218-222.
11. J. A. Stamford, C. Davidson, D. P. McLaughlin, S. E. Hopwood, Trends Neurosci. 2000, 23, 459-463.
12. R. Martin-Ruiz, L. Ugedo, Neuropharmacology 2001, 41, 72-78.
13. J. R. Boot, G. Brace, C. L. Delatour, N. Dezutter, et al., Bioorg. Med. Chem. Lett. 2004, 14, 5395-5399.
14. C. Roberts, G. W. Price, B. J. Jones, J. Pharmacol. 1997, 36, 549-557.
15. C. Stenfors, T. Magnusson, L. G. Larsson, H. Yu, et al., Arch. Pharmacol. 1999, 359, 110-116.
16. F. Artigas, CNS Drugs 1999, 54, 79-89.
17. P. V. Tran, F. P. Bymaster, R. K. McNamara, W. Z. Potter, J. Clin. Psychopharmacol. 2003, 23, 78-86.
18. F. P. Bymaster, E. E. Beedle, J. Findlay, P. T. Gallagher, et al., Bioorg. Med. Chem. Lett. 2003, 13, 44-77.
19. TSAR 3.3 Accelrys, Oxford Molecular Limited, 2000.
20. J. Klocker, B. Wailzer, G. Buchbauer, P. Wolschann, J. Chem. Inf. Comput. Sci. 2002, 42, 1443-1449.
21. A. Kovatcheva, G. Buchbauer, A. Golbraikh, P. Wolschann, J. Chem. Inf. Comput. Sci. 2003, 43, 259-266.
22. H. Kubinyi, Drug Disc. Today 1997, 2, 457-467.
23. N. Dessalew, P. V. Bharatam, Eur. J. Med. Chem. 2007, 42, 1014-1027.
24. N. Dessalew, D. S. Patel, P. V. Bharatam, J. Mol. Graph. Mod. 2007, 25, 885-895.
25. N. Dessalew, P. V. Bharatam, S. K. Singh, QSAR Comb. Sci. 2007, 26, 85-91.
26. M. H. Knaggs, C. McGuigan, S. A. Harris, P. Heshmati, et al., Bioorg. Med. Chem. Lett. 2000, 10, 2075-2078.
27. H. J. Chang, H. J. Kim, H. S. Chun, Life Sci. 2007, 80, 835-841.
28. B. B. Lohray, N. Gandhi, K. B. Srivastava, V. B. Lohray, Bioorg. Med. Chem. Lett. 2006, 16, 3817-3823.
29. J. M. J. Tronchet, M. Grigorov, N. Dolatshahi, F. Moriaud, G. Weber, Eur. J. Med. Chem. 1997, 32, 279-299.
30. J. A. Ignacio, A. Jesus, M. A. Jose, I. D. Ana, et al., Bioorg. Med. Chem. 2006, 14, 4361-4372.
31. J. A. Ignacio, A. Jesus, M. A. Jose, M. A. Rosa, et al., Bioorg. Med. Chem. Lett. 2003, 13, 2719-2725.
32. T. Kumiko, J. K. Todd, A. H. Nicholas, P. R. Vincent, et al., Bioorg. Med. Chem. Lett. 2003, 13, 1903-1905.
33. Z. Dahui, L. H. Boyd, S. Uresh, H. A. Terrance, et al., Bioorg. Med. Chem. Lett. 2006, 16, 1338-1341.
34. J. Andres, J. Med. Chem. 2005, 48, 2054-2071.
35. A. Kling, H. Mack, H. M. Margot, K. U. Drescher, et al., Bioorg. Med. Chem. Lett. 2005, 15, 5567-5573.
36. ChemDraw 8.0: CambridgeSoft Life Science Enterprise Solution, 100 Cambridge Park Drive, Cambridge, MA 02140, USA.
37. A. Verloop, H. W. J. Tipker in Drug Design (Ed.: E. J. Ariens), Academic Press, New York, 1976, 7, pp. 165-207.
38. A. Verloop, H. W. J. Tipker, Pestic. Sci. 1976, 7, 379-390.
39. A. Verloop, J. Tipker in Biological activity and chemical structure (Ed.: J. A. Keverling Buisman), Elsevier, Amsterdam, 1977, pp. 63-81.